argenx (NASDAQ:ARGX) Price Target Raised to $704.00

argenx (NASDAQ:ARGX - Get Free Report) had its price target hoisted by stock analysts at Oppenheimer from $675.00 to $704.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Oppenheimer's price target would indicate a potential upside of 13.32% from the company's current price.

Several other brokerages have also recently commented on ARGX. Scotiabank upgraded shares of argenx from a "sector perform" rating to a "sector outperform" rating and raised their target price for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. HC Wainwright boosted their target price on shares of argenx from $717.00 to $720.00 and gave the company a "buy" rating in a research note on Friday. JPMorgan Chase & Co. raised their target price on argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research report on Monday, November 4th. Guggenheim upped their price target on argenx from $585.00 to $665.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Finally, Wolfe Research raised argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price objective for the company in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $662.83.

Remove Ads

argenx Stock Down 0.2 %

argenx stock traded down $1.36 during mid-day trading on Friday, hitting $621.25. The company's stock had a trading volume of 285,887 shares, compared to its average volume of 273,997. argenx has a twelve month low of $349.86 and a twelve month high of $678.21. The stock's fifty day moving average price is $642.51 and its two-hundred day moving average price is $591.91. The stock has a market capitalization of $37.75 billion, a P/E ratio of -705.97 and a beta of 0.58.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. Equities analysts expect that argenx will post 3.13 earnings per share for the current year.

Institutional Trading of argenx

Several large investors have recently made changes to their positions in the stock. GeoWealth Management LLC lifted its holdings in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after purchasing an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of argenx during the 4th quarter worth $37,000. Global Retirement Partners LLC grew its stake in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd acquired a new position in argenx during the 4th quarter worth $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in argenx during the 4th quarter worth $38,000. Institutional investors own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.